8th Feb 2021 14:27
Verici Dx PLC - clinical diagnostics developer for organ transplant - Says it is now accelerating its clinical laboratory improvement amendments laboratory opening and approvals strategy for its products Clarava and Tuteva. Strategy includes the appointment of David Schultenover as vice president of Quality & Regulatory with immediate effect, responsible for the delivery of clinical laboratory improvement amendments laboratory approvals. Schultenover joins Verici Dx from Thermo Fisher Scientific, where he was senior director of Regulatory, Quality & Compliance.
"[Schultenover's] track record of leading teams that meet and exceed expectations, and his experience in developing and implementing processes and procedures that improve company efficiencies will allow us to ensure we work to accelerate the timelines for opening CLIA [clinical laboratory improvement amendments] laboratories and obtaining CLIA approvals as outlined at IPO. This is an important step in the commercialisation journey for our innovative transplant products and we are pleased to be expanding our management resources to help expedite CLIA approvals for our laboratories," says Chief Executive Sara Barrington.
Current stock price: 92.70 pence
Year-to-date change: up 59%
By Zoe Wickens; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Verici Dx